Cargando…

Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung cancer

INTRODUCTION: Next-generation sequencing (NGS) is currently widely used for biomarker studies and molecular profiling to identify concurrent alterations that can lead to the better characterization of a tumor’s molecular landscape. However, further evaluation of technical aspects related to the dete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clavé, Sergi, Jackson, Jennifer B., Salido, Marta, Kames, Jacob, Gerding, Kelly M. R., Verner, Ellen L., Kong, Eric F., Weingartner, Elizabeth, Gibert, Joan, Hardy-Werbin, Max, Rocha, Pedro, Riera, Xènia, Torres, Erica, Hernandez, James, Cerqueira, Gustavo, Nichol, Donna, Simmons, John, Taus, Álvaro, Pijuan, Lara, Bellosillo, Beatriz, Arriola, Edurne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623306/ https://www.ncbi.nlm.nih.gov/pubmed/37927472 http://dx.doi.org/10.3389/fonc.2023.1225646

Ejemplares similares

MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)
por: Casadevall, David, et al.
Publicado: (2015)

MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside
por: Hardy-Werbin, Max, et al.
Publicado: (2019)

ROS1 copy number alterations are frequent in non-small cell lung cancer
por: Clavé, Sergi, et al.
Publicado: (2016)

Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC
por: Rocha, Pedro, et al.
Publicado: (2020)

EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2019)

MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines
por: Arriola, E, et al.
Publicado: (2011)

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2023)

Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry
por: Conde, Esther, et al.
Publicado: (2014)

EGFR-Mutant Lung Adenocarcinoma Mimicking a Pneumonia
por: Taus, Álvaro, et al.
Publicado: (2012)

Multiple Brain Pseudoprogression in a Patient With NSCLC Treated With Pembrolizumab
por: Moliner, Laura, et al.
Publicado: (2020)

High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients
por: Cañadas, Israel, et al.
Publicado: (2014)

Comparison between Immunocytochemistry, FISH and NGS for ALK and ROS1 Rearrangement Detection in Cytological Samples
por: Frankel, Diane, et al.
Publicado: (2022)

Identification of ALK Gene Alterations in Urothelial Carcinoma
por: Bellmunt, Joaquim, et al.
Publicado: (2014)

Impact of Pre-Analytical Conditions on the Antigenicity of Lung Markers: ALK and MET
por: Miller, Rachel, et al.
Publicado: (2020)

CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer
por: Olingy, Claire, et al.
Publicado: (2022)

MultiCOVID: a multi modal deep learning approach for COVID-19 diagnosis
por: Hardy-Werbin, Max, et al.
Publicado: (2023)

Multiplexed Exchange-PAINT imaging reveals ligand-dependent EGFR and Met interactions in the plasma membrane
por: Werbin, Jeffrey L., et al.
Publicado: (2017)

Crizotinib Exhibits Antitumor Activity by Targeting ALK Signaling not c-MET in Pancreatic Cancer
por: Yan, Hong Hua, et al.
Publicado: (2014)

Centrifugal Atomization of Glass-Forming Alloy Al(86)Ni(8)Y(4.5)La(1.5)
por: Pijuan, Jordi, et al.
Publicado: (2022)

NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment
por: Sánchez‐Herrero, Estela, et al.
Publicado: (2021)

SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer
por: Papadakis, Andreas I, et al.
Publicado: (2015)

Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR
por: Narayanan, Dilip, et al.
Publicado: (2017)

Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
por: Guerreiro Stucklin, Ana S., et al.
Publicado: (2019)

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS
por: Korpanty, Grzegorz J., et al.
Publicado: (2014)

Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition
por: Megiorni, Francesca, et al.
Publicado: (2015)

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
por: Chen, Rui-Lian, et al.
Publicado: (2018)

EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
por: Colombino, Maria, et al.
Publicado: (2019)

Acquired Exon 14 MET Mutation Associated With Resistance to Alectinib in a Patient With ALK–Rearranged NSCLC
por: Daniel, Catherine, et al.
Publicado: (2020)

Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma
por: Cruickshanks, Nichola, et al.
Publicado: (2017)

The potential role of HGF-MET signaling and autophagy in the war of Alectinib versus Crizotinib against ALK-positive NSCLC
por: Huang, Xing
Publicado: (2018)

Immunotherapy and brain metastasis in lung cancer: connecting bench side science to the clinic
por: Rios-Hoyo, Alejandro, et al.
Publicado: (2023)

A Novel LOC101927967 Intergenic Region ALK Fusion Identified by NGS and Validated by IHC and FISH in a Patient with Early Stage Adenocarcinoma of Lung
por: Jia, Xiaojing, et al.
Publicado: (2022)

EML4-ALK Gene Mutation Detected with New NGS Lung Cancer Panel CDx Using Sputum Cytology in a Case of Advanced NSCLC
por: Morikawa, Kei, et al.
Publicado: (2023)

Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing
por: Conde, Esther, et al.
Publicado: (2022)

Addendum to the NGS report
por: CERN. Geneva. SPS-PS Experiments Committee
Publicado: (1999)

NGS-Logistics: federated analysis of NGS sequence variants across multiple locations
por: Ardeshirdavani, Amin, et al.
Publicado: (2014)

CSI NGS Portal: An Online Platform for Automated NGS Data Analysis and Sharing
por: An, Omer, et al.
Publicado: (2020)

ngsComposer: an automated pipeline for empirically based NGS data quality filtering
por: Kuster, Ryan D, et al.
Publicado: (2021)

Discordance between FISH, IHC, and NGS Analysis of ALK Status in Advanced Non–Small Cell Lung Cancer (NSCLC): a Brief Report of 7 Cases()
por: Scattone, Anna, et al.
Publicado: (2018)

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
por: Damm-Welk, Christine, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_egs6sok8htdfh1754e5j2hvk8u